Related Experiment Video
Updated: Aug 8, 2026
Culture of myeloid dendritic cells from bone marrow precursors
Published on: July 26, 2008
Heparin induces differentiation of CD1a+ dendritic cells from monocytes: phenotypic and functional characterization
1Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA.
Insights
Heparin reliably induces CD1a+ dendritic cells (DCs) from monocytes, offering a new method for immunotherapy. This process works with or without human serum, expanding potential applications for dendritic cell therapies.
Area of Science:
- Immunology
- Cell Biology
- Biotechnology
Background:
- Dendritic cells (DCs) are crucial for initiating and regulating immune responses.
- CD1a+ DCs are derived from human monocytes but are difficult to generate using human serum or plasma.
- Existing methods often rely on fetal calf serum (FCS), limiting clinical applications.
Purpose of the Study:
- To investigate heparin's ability to induce CD1a+ DC differentiation from monocytes.
- To characterize the phenotype and function of heparin-induced CD1a+ DCs.
- To explore the potential of heparin-treated DCs for immunotherapy.
Main Methods:
- Monocytes were cultured with varying concentrations of heparin in the presence or absence of autologous serum/plasma.
- Phenotypic analysis of CD1a+ and CD1a- DCs was performed using flow cytometry, assessing markers like CD40, CD80, CD86, and HLA-DR.
- Functional assays included stimulation with LPS and/or IFN-gamma to measure cytokine production (IL-10, IL-12) and T cell priming assays.
Main Results:
- Heparin reliably induced CD1a+ DC differentiation from monocytes in a dose-dependent manner (0-50 U/ml).
- CD1a+ DCs exhibited distinct surface marker expression (higher CD40/CD80, lower CD86) compared to CD1a- DCs.
- Heparin-treated DCs produced more IL-10 and less IL-12 upon stimulation and were more potent in priming CD4+ T cells for proliferation and cytokine production.
Conclusions:
- Heparin offers a novel and reliable method for generating CD1a+ DCs from human monocytes ex vivo, without xenogeneic serum.
- Heparin-induced CD1a+ DCs possess unique functional properties that enhance T cell responses.
- These findings suggest a promising new approach for developing dendritic cell-based immunotherapies.
Abstract:
Dendritic cells (DCs) play important roles in initiation and regulation of immune responses. DCs derived from human monocytes can be classified according to presence of CD1a molecules. Although CD1a+ DCs can be prepared from monocytes in media containing GM-CSF, IL-4, and FCS, it has been reported that CD1a+ DCs could not be easily obtained from monocytes using media containing human serum or plasma. In this study, we demonstrate for the first time that heparin can reliably induce differentiation of CD1a+ DCs from monocytes with or without autologous serum or plasma. The development of CD1a+ DCs is heparin concentration dependent (0-50 U/ml). Comparing with CD1a- DCs developed without heparin, CD1a+ DCs express higher CD40 and CD80 and lower CD86. Both CD1a+ and CD1a- DCs express similar levels of HLA-DR. CD80, CD86, HLA-DR, and CD40 are proportionally up-regulated when both types of DCs are stimulated with LPS or LPS plus IFN-gamma. The effect of heparin is neutralized by heparin-binding proteins, such as protamine sulfate, platelet factor-4, and beta-thromboglobulin. Functionally, heparin-treated DCs respond to LPS or LPS plus IFN-gamma with higher IL-10 and less IL-12 production than heparin-untreated DCs. Heparin-treated DCs are more potent in priming allogeneic and autologous CD4+ T cells to proliferate and to produce both type 1 and type 2 cytokines. The results of our study show that CD1a+ DCs can be prepared from monocytes ex vivo without using xenogeneic serum and may be used for immunotherapy.
